)
)
)
Lucina Biotherapeutics
Lucina Biotherapeutics is developing a first-in-class therapy for dry age-related macular degeneration by restoring essential retinal lipids that decline due to gene silencing, a root cause of early disease progression. Our lead candidate, LUC-101, replenishes these lipids to reverse the structural and functional deficits that drive early-stage dry AMD. This approach is supported by strong genetic validation and published preclinical efficacy. Lucina’s synthetic biology platform also enables follow-on programs for neurologic and metabolic disorders.
Address
Santa CruzCalifornia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)